DOCSLIB.ORG

AMM Périmées Au 09 Mars 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
AMM Périmées Au 09 Mars 2018 MINSANTE/SG/DPML AMM périmées au 09 mars 2018 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption 3M SANTE 2720011 APURONE FLUMEQUINE 400 mg Comprimé / B/30 3M SANTE 13/02/1990 05/07/2002 Tablet 3M SANTE 2720021 ASPIRINE PH8 ACIDE ACETYL 0,50 g Comprimé / B/50 3M SANTE 03/04/1990 05/07/2002 SALICYLIQUE Tablet 3M SANTE 2720022 ASPIRINE PH8 ACIDE ACETYL 0,50 g Comprimé / B/20 3M SANTE 03/04/1990 05/07/2002 SALICYLIQUE Tablet 3M SANTE 2720041 THEOLAIRE LP THEOPHILINE 175 mg Comprimé / B/30 3M SANTE 03/04/1990 05/07/2002 Tablet 3M SANTE 2720031 CONTALAX BISACODYL 5 mg Comprimé / B/30 3M SANTE 03/04/1990 05/07/2002 Tablet 3M SANTE 2720042 THEOLAIRE LP THEOPHILINE 100 mg Comprimé / B/30 3M SANTE 06/05/1997 06/11/1998 Tablet ABBOTT France 7100011 BRUFEN IBUPROFENE 400 mg Comprimé B/30 ABBOTT Products 21/04/2002 15/11/2017 enrobé/Sugar SAS coated tablet ABBOTT France 6630011 FORENE ISOFLURANE LIQUIDE FLACON/25 ABBOTT France 11/07/2005 11/01/2017 POUR 0 ML INHALATION ABBOTT France 3971101 SEVORANE Sévoflurane SOLUTION Fl/250 ml ABBVIE LTD 19/06/2012 19/12/2013 POUR PULVERISAT ION BUCCALE ABBOTT France 3970081 ISOBAR METHYCLOTHIAZID 5mg/150 mg Comprimé B/30 ABBOTT France 10/10/2001 10/10/2006 E+TRIAMTERENE sécable ABBOTT France 3970061 MUCOLATOR ACETYLCYSTEINE 200 mg Poudre pour B/30 ABBOTT Pty LTD 28/01/2005 28/07/2006 solution buvable Page 1 de 377 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption ABBOTT France 3970011 NAXY CLARITHROMYCINE 500 MG Comprimé B/10 ABBOTT France 19/07/2002 19/01/2004 enrobé/Sugar coated tablet ABBOTT France 3970013 NAXY CLARITHROMYCINE 500 mg Comprimé B/14 ABBOTT France 19/07/2002 19/01/2004 enrobé/Sugar coated tablet ABBOTT France 3970012 NAXY CLARITHROMYCINE 25 mg/ml Granulés pour Flacon/100 ABBOTT France 19/07/2002 19/01/2004 suspension ml buvable ABBOTT Products 3330071 PHYSIOTENS® MOXONIDINE 0,20 mg Comprimé B/30 ABBOTT Products 31/03/2004 19/10/2017 SAS pelliculé/Coat SAS ed tablet ABBOTT Products 3330081 PHYSIOTENS® MOXONIDINE 0,40 mg Comprimé B/30 ABBOTT Products 31/03/2004 19/10/2017 SAS pelliculé/Coat SAS ed tablet ABBOTT Products 3330111 DICETEL PINAVERIUM 100 mg Comprimé B/30 ABBOTT Products 03/10/2005 19/10/2017 SAS pelliculé/Coat SAS ed tablet ABBOTT Products 10941501 TULLE GRAS M.S. Pansement interface 10cm x 10cm COMPRESSE B/10 ABBOTT Products 07/11/2010 08/05/2017 SAS vaseliné stérile SAS ABBOTT Products 3330102 DUSPATALIN MEBEVERINE 200 mg Gélule/Capsul B/30 ABBOTT 01/10/2010 01/04/2017 SAS e BIOLOGICALS BV ABBOTT Products 10940101 BETASERC DICHLORHYDRATE 24 mg Comprimé / B/60 ABBOTT 01/04/2007 01/04/2017 SAS DE BETAHISTIDINE Tablet HEALTHCARE SAS ABBOTT Products 3330031 DUSPASTALIN MEBEVERINE 100 MG Comprimé B/30 ABBOTT 08/05/2002 08/05/2007 SAS pelliculé/Coat BIOLOGICALS BV ed tablet Page 2 de 377 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption ABBVIE LTD 6621414 KALETRA® LOPINAVIR ET (80 mg + 20 Solution B/5 flacons AESICA 09/07/2014 08/01/2016 RITONAVR mg)/ml buvable de 60 ml QUEENBOROUGH chacun Limited ABBVIE LTD 7051302 ALUVIA LOPINAVIR / 200mg/50mg Comprimé B/120 ABBVIE 21/08/2013 20/02/2015 RITONAVIR pelliculé/Coat DEUTSCHLAND ed tablet GmbH & Co.KG ABBVIE LTD 7051301 ALUVIA® LOPINAVIR / 100mg/50 mg Comprimé B/60 ABBVIE 21/08/2013 20/02/2015 RITONAVIR pelliculé/Coat DEUTSCHLAND ed tablet GmbH & Co.KG ABBVIE LTD 10840111 TRONOTHANE PRAMOCAINE 1% Gel pour T/30 g ABBVIE LTD 01/10/2010 01/04/2012 application cutanée ACINO PHARMA AG 2410104 ARTEQUIN® ARTESUNATE+ 50mg/125mg MICROGRAN B/3 sticks MEPHA Ltd 17/05/2006 16/11/2017 Pédiatrique MEFLOQUINE ULES EN SACHET ACINO PHARMA AG 2410101 OLFEN® 75 retard , DICLOFENAC 75 mg Depotaps B/30 ACINO PHARMA 15/03/2002 15/03/2017 SODIUM AG ACINO PHARMA AG 2410071 BACTIFLOX CIPROFLOXACINE 250 MG Comprimé / B/10 ACINO PHARMA 08/07/1998 14/03/2017 Tablet AG ACINO PHARMA AG 2410072 BACTIFLOX CIPROFLOXACINE 500 mg Comprimé / B/10 ACINO PHARMA 08/07/1998 14/03/2017 Tablet AG ACINO PHARMA AG 9731409 ARTEQUIN™-600/750, ARTESUNATE+ 600mg/750mg Comprimé B/6 ACINO PHARMA 11/07/2000 10/01/2017 MEFLOQUINE pelliculé AG sécable ACINO PHARMA AG 9731407 TRABAR™-50, TRAMADOL 50mg Gélule/Tablet B/10 ACINO PHARMA 11/07/2000 10/01/2017 AG ACINO PHARMA AG 9731408 TRABAR™-100, TRAMADOL 100mg/2ml Suspension B/5 ACINO PHARMA 11/07/2000 10/01/2017 injectable AG ACINO PHARMA AG 9731404 MESPORIN™-2000 IV, CEFTRIAXONE 2000 mg Poudre pour B/1 ACINO PHARMA 11/07/2000 10/01/2017 perfusion AG ACINO PHARMA AG 9731403 MESPORIN™-500 IM, CEFTRIAXONE 500 mg Poudre pour Fl/1+solvant ACINO PHARMA 11/07/2000 10/01/2017 préparation AG injectable Page 3 de 377 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption ACINO PHARMA AG 9731402 MESPORIN™-1000 IV, CEFTRIAXONE 1000 mg Poudre pour Fl/1+solvant ACINO PHARMA 11/07/2000 11/12/2016 préparation AG injectable ACINO PHARMA AG 9731401 MESPORIN™-1000 IM, CEFTRIAXONE 1000 mg Poudre pour Fl/1+solvant ACINO PHARMA 11/07/2000 11/12/2016 préparation AG injectable ACINO PHARMA AG 2410254 AZITRO-ACINO™ AZITHROMYCINE 250 mg Comprimé B/3 ACINO PHARMA 01/04/2010 30/09/2016 pelliculé/Coat AG ed tablet ACINO PHARMA AG 2410253 AZITRO-ACINO™ AZITHROMYCINE 500 mg Comprimé B/3 ACINO PHARMA 01/04/2010 30/09/2016 pelliculé/Coat AG ed tablet ACINO PHARMA AG 2410016 OLFEN® 75 I.M. , DICLOFENAC 75 mg Solution B/3 ACINO PHARMA 12/01/2015 13/07/2016 SODIUM injectable AG ACINO PHARMA AG 2410011 OLFEN® DICLOFENAC 50 mg LACTAB B/20 ACINO PHARMA 08/12/1997 11/07/2016 SODIUM AG ACINO PHARMA AG 2410013 OLFEN®-100 Retard , DICLOFENAC 100 mg Depocaps B/10 ACINO PHARMA 08/12/1997 11/07/2016 SODIUM AG ACINO PHARMA AG 2410014 OLFEN® DICLOFENAC 100 mg RECTOCAPS B/5 ACINO PHARMA 08/12/1997 11/07/2016 SODIUM AG ACINO PHARMA AG 2410015 OLFEN®-Gel DICLOFENAC 1 g Gel pour T/50g ACINO PHARMA 08/12/1997 11/07/2016 SODIUM application AG cutanée ACINO PHARMA AG 2410103 ARTEQUIN® ARTESUNATE+ 100mg/135mg Comprimé B/3+3 MEPHA Ltd 12/06/2009 11/12/2015 MEFLOQUINE enrobé/Sugar coated tablet ACINO PHARMA AG 9731405 XYLO-ACINO™ 0,05% XYLOMETAZOLINE 5 mg SPRAY Fl/10ml ACINO PHARMA 11/07/2000 13/02/2015 Enfant NASAL AG ACINO PHARMA AG 9731406 XYLO-ACINO™ 0,1% XYLOMETAZOLINE 10 mg SOLUTE Fl/10ml ACINO PHARMA 11/07/2000 13/02/2015 Adulte NASAL AG ACINO PHARMA AG 2410202 GASEC OMEPRAZOLE 10 mg Gastrocaps B/14 MEPHA Ltd 12/06/2009 11/12/2010 Page 4 de 377 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption ACINO PHARMA AG 2410102 ARTEQUIN ARTESUNATE+ 600/1500 mg Comprimé B/3+6 MEPHA Ltd 12/06/2009 11/12/2010 MEFLOQUINE enrobé/Sugar coated tablet ACINO PHARMA AG 2410031 DOLOBENE GEL MULTIPLE Gel pour T/20 g ACINO PHARMA AG 08/07/1998 15/03/2007 application cutanée ACINO PHARMA AG 2410062 GASEC OMEPRAZOLE 20 MG Gastrocaps B/7 ACINO PHARMA AG 08/07/1998 14/03/2007 ACINO PHARMA AG 2410121 ZETRY-MEPHA R CETIRIZINE 10 mg Comprimé B/20 SOFARIMEX, 03/10/2005 03/02/2007 enrobé/Sugar Industrial Quimica e coated tablet Farmacêutica S.A. ACINO PHARMA AG 2420181 PECTORAL MULTIPLE MULTIPLE Sirop/Syrup Flacon/100 ACINO PHARMA 05/07/2004 05/01/2006 ml AG ACINO PHARMA AG 2410012 OLFEN 75 DICLOFENAC 75 mg AMPOULE/VI B/5 ACINO PHARMA AG 08/12/1997 11/07/2005 SODIUM AL ACINO PHARMA AG 2410021 VITIRON MULTIVITAMINES+S / CAPSULES B/10 ACINO PHARMA AG 08/12/1997 11/07/2005 ELS MINERAUX. ACINO PHARMA AG 2410131 ARTEQUIN ARTESUNATE+ 200/250 Comprimé / B/3/3 MEPHA Ltd 24/07/2002 24/01/2004 MEFLOQUINE Tablet ACINO PHARMA AG 2410085 PLASMOTRIM ARTESUNATE 50 mg LACTAB B/600 ACINO PHARMA AG 08/05/2002 08/11/2003 ACINO PHARMA AG 2410086 PLASMOTRIM ARTESUNATE 200 mg LACTAB B/600 ACINO PHARMA AG 08/05/2002 08/11/2003 ACINO PHARMA AG 2410087 PLASMOTRIM ARTESUNATE 50 mg LACTAB B/150 ACINO PHARMA AG 08/05/2002 08/11/2003 ACINO PHARMA AG 2410088 PLASMOTRIM ARTESUNATE 200 mg RECTOCAPS B/150 ACINO PHARMA AG 08/05/2002 08/11/2003 ACINO PHARMA AG 2410091 BACTIFLOX CIPROFLOXACINE 750 MG LACTAB Comprimé / B/10 ACINO PHARMA AG 08/05/2002 08/11/2003 Tablet ACINO PHARMA AG 2410083 PLASMOTRIM ARTESUNATE 200 mg LACTAB B/6 ACINO PHARMA AG 18/12/1998 18/06/2000 Page 5 de 377 Titulaire AMM Nom commercial DCI Dosage Forme PrésentationFabricant Date AMM Peremption ACINO PHARMA AG 2410084 PLASMOTRIM ARTESUNATE 200 mg RECTOCAPS B/6 ACINO PHARMA AG 18/12/1998 18/06/2000 ACINO PHARMA AG 2410081 PLASMOTRIM ARTESUNATE 50 mg LACTAB B/12 ACINO PHARMA AG 18/12/1998 18/06/2000 ACINO PHARMA AG 2410082 PLASMOTRIM 50 MG ARTESUNATE 50 mg RECTOCAPS B/6 ACINO PHARMA AG 18/12/1998 18/06/2000 ACINO PHARMA AG 2410041 NOPIL FORTE SULFAMETHOXAZO 960 mg Comprimé / B/10 ACINO PHARMA AG 08/07/1998 08/01/2000 LE + Tablet TRIMETHOPRIME Adams 7711402 Amicoz® NITRATE DE 2% CREME T/15g Adams 09/07/2014 08/01/2016 Pharmaceutical MICONAZOLE DERMIQUE Pharmaceutical (ANHUI) Co.,Ltd (ANHUI) Co.,Ltd Adhe-els.sa 15091402 NEOFIL + (suture, USP CONSOMMABLE suture Boite de 24 Adhe-els.sa 08/07/2014 07/01/2016 1,36mm) (hopital) chirurgicale synthétique résorbable tressé violet Adhe-els.sa 15091401 NEOFIL + (suture, USP CONSOMMABLE suture Boite de 24 Adhe-els.sa 08/07/2014 07/01/2016 1/0,36mm) (hopital) chirurgicale synthétique résorbable tressé violet Adhe-els.sa 15091403 NEOFIL + (ligature, USP CONSOMMABLE suture Boite de 24 Adhe-els.sa 08/07/2014 07/01/2016 2/0,26mm) (hopital) chirurgicale synthétique résorbable tressé violet Adhe-els.sa 15091407 POLAMIDE M NOIR CONSOMMABLE suture Boite de 36 Adhe-els.sa 08/07/2014 07/01/2016 (ligature, USP (hopital) chirurgicale 3/0,24mm) synthétique résorbable
Load more

Recommended publications
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya Et Al
    US 2006.0024.365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0024365A1 Vaya et al. (43) Pub. Date: Feb. 2, 2006 (54) NOVEL DOSAGE FORM (30) Foreign Application Priority Data (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN)................................. 699/MUM/2002 Singh Karan, Gujarat (IN); Sunil Aug. 5, 2002 (IN). ... 697/MUM/2002 Sadanand, Gujarat (IN); Vinod Kumar Jan. 22, 2003 (IN)................................... 80/MUM/2003 Gupta, Gujarat (IN) Jan. 22, 2003 (IN)................................... 82/MUM/2003 Correspondence Address: Publication Classification HEDMAN & COSTIGAN P.C. (51) Int. Cl. 1185 AVENUE OF THE AMERICAS A6IK 9/22 (2006.01) NEW YORK, NY 10036 (US) (52) U.S. Cl. .............................................................. 424/468 (22) Filed: May 19, 2005 A dosage form comprising of a high dose, high Solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of Related U.S. Application Data immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of (63) Continuation-in-part of application No. 10/630,446, modified release active ingredient per unit is from 500 mg to filed on Jul. 29, 2003. 1500 mg, a process for preparing the dosage form. Patent Application Publication Feb. 2, 2006 Sheet 1 of 10 US 2006/0024.365A1 FIGURE 1 FIGURE 2 FIGURE 3 Patent Application Publication Feb. 2, 2006 Sheet 2 of 10 US 2006/0024.365A1 FIGURE 4 (a) 7 FIGURE 4 (b) Patent Application Publication Feb. 2, 2006 Sheet 3 of 10 US 2006/0024.365 A1 FIGURE 5 100 ov -- 60 40 20 C 2 4.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
    IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 1/89 PROTOCOL TITLE: EFFICACY OF DIOSMECTITE (SMECTA®) IN THE SYMPTOMATIC TREATMENT OF ACUTE DIARRHOEA IN ADULTS. A MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY STUDY PROTOCOL STUDY number: F-FR-00250-105 (Diosmectite- BN 00250) EudraCT number: n° 2015-001138-10 Final Version (with Amendment No. 4): 07 January 2019 Sponsor’s Medically Responsible Person: Study Sponsor: PPD Ipsen Pharma SAS PPD 65 quai Georges Gorse Ipsen Pharma SAS 92100 Boulogne-Billancourt, France 65 quai Georges Gorse Tel: PPD 92100 Boulogne-Billancourt, France Fax: PPD Tel: PPD Fax: PPD Monitoring Office: and/or CRO Co-ordinating Investigator: PPD PPD PPD Délégation à la Recherche Ipsen Pharma SAS Centre Hospitalier Régional Universitaire 65 quai Georges Gorse de Lille 92100 Boulogne-Billancourt, France 2, avenue Oscar Lambret, Tel: PPD 59037 Lille, France Cedex Fax: PPD Tel: PPD Fax: PPD Pharmacovigilance/Emergency Contact: PPD Ipsen Innovation, ZI de Courtaboeuf - 5 avenue du Canada - 91940 Les Ulis - France Tel: PPD Tel: PPD – PPD For SAEs reporting: Fax: PPD Email: PPD Persons supplied with this information must understand that it is strictly confidential. Information contained herein cannot be disclosed, submitted for publication or used for any purpose other than that contemplated herein without the sponsor’s prior written authorisation. IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 2/89 INVESTIGATOR’S AGREEMENT Investigator Agreement and Signature: I have read and agree to Protocol F-FR-00250-105 entitled Efficacy of the diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen Et Al
    US009283192B2 (12) United States Patent (10) Patent No.: US 9,283,192 B2 Mullen et al. (45) Date of Patent: Mar. 15, 2016 (54) DELAYED PROLONGED DRUG DELIVERY 2009. O1553.58 A1 6/2009 Diaz et al. 2009,02976O1 A1 12/2009 Vergnault et al. 2010.0040557 A1 2/2010 Keet al. (75) Inventors: Alexander Mullen, Glasgow (GB); 2013, OO17262 A1 1/2013 Mullen et al. Howard Stevens, Glasgow (GB); Sarah 2013/0022676 A1 1/2013 Mullen et al. Eccleston, Scotstoun (GB) FOREIGN PATENT DOCUMENTS (73) Assignee: UNIVERSITY OF STRATHCLYDE, Glasgow (GB) EP O 546593 A1 6, 1993 EP 1064937 1, 2001 EP 1607 O92 A1 12/2005 (*) Notice: Subject to any disclaimer, the term of this EP 2098 250 A1 9, 2009 patent is extended or adjusted under 35 JP HO5-194188 A 8, 1993 U.S.C. 154(b) by 0 days. JP 2001-515854. A 9, 2001 JP 2001-322927 A 11, 2001 JP 2003-503340 A 1, 2003 (21) Appl. No.: 131582,926 JP 2004-300148 A 10, 2004 JP 2005-508326 A 3, 2005 (22) PCT Filed: Mar. 4, 2011 JP 2005-508327 A 3, 2005 JP 2005-508328 A 3, 2005 (86). PCT No.: PCT/GB2O11AOOO3O7 JP 2005-510477 A 4/2005 JP 2008-517970 A 5, 2008 JP 2009-514989 4/2009 S371 (c)(1), WO WO99,12524 A1 3, 1999 (2), (4) Date: Oct. 2, 2012 WO WOO1 OO181 A2 1, 2001 WO WOO3,O266.15 A2 4/2003 (87) PCT Pub. No.: WO2011/107750 WO WOO3,O26625 A1 4/2003 WO WO 03/026626 A2 4/2003 PCT Pub.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]